AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha]
Last acelrx pharmaceuticals, inc earnings: 11/6 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations: ir.acelrx.com/investor-relations
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q2 2019 Results - Earnings Call Transcript AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX CompanyParticipants Vince Angotti - Chief Executive Officer Raffi Asadorian - Chief Financial Officer Pam Palmer - Chief Medical Officer and Co-Founder Jacob Hutchins - Anesthesiologist and Associate Professor, Department of Anesthesiology Conference CallParticipants Brandon Folkes - Cantor Fitzgerald Randall Stanicky - RBC Capital Markets Ed Arce - H.C. Wainwright Chris Howerton - Jefferies Andrew D'Silva - B Riley FBR Michael Higgins - Ladenburg Thalman Operator Welcome to the AcelRx Second Quarter 2019 Conference Call. This call is being webcast live on the Events page of the Investors section of AcelRx's website at acelrx.com. This call is the property of AcelRx and any recording, reproduction, or transmission of this call without the express written consent of AcelRx is strictly prohibited. As a reminder, today's call is being recorded. Yo
[Read more]
| Impact snapshot | Event time: | ACRX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
ACRX alerts
ACRX alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRX alerts
High impacting AcelRx Pharmaceuticals, Inc news events
Weekly update
A roundup of the hottest topics
ACRX
News
- AcelRx Pharmaceuticals Announces Publication Analyzing Pooled Dosing and Efficacy Data on Sufentanil Sublingual 30 mcg TabletsPR Newswire
- AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $2.25 price target on the stock.MarketBeat
- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX): Is Breakeven Near? [Yahoo! Finance News]Yahoo! Finance News
- AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) was downgraded by analysts at Credit Suisse Group AG from an "outperform" rating to a "neutral" rating. They now have a $2.00 price target on the stock, down previously from $7.00.MarketBeat
- Closing Out a Position After Disappointing Results [TheStreet.com]TheStreet.com
- More
ACRX
SEC Filings
- 11/12/19 - Form 4
- 11/12/19 - Form 4
- 11/7/19 - Form 10-Q
- ACRX's page on the SEC website
- More